Newron delays schizophrenia drug trial after FDA raises concerns

Swiss-listed drugmaker Newron must delay a trial of its prospective schizophrenia medicine evenamide after the U.S. Food and Drug Administration raised concerns about central nervous system (CNS) events that have emerged in rats and dogs.

from Reuters: Health News https://reut.rs/30LMGnx
via IFTTT